Press Releases

For the third time in a row, the German Packaging Institute (Deutsches Verpackungsinstitut e.V.) has honored Syntegon with the German Packaging Award. The new development Versynta microBatch convinced the jury in the category “packaging machines”. The highly flexible and fully automated production cell with gloveless isolator fills and closes smallest batches of pharmaceuticals and biopharmaceuticals safely and with virtually no product loss.   Innova

 SciSparc Ltd. a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0). The

PureTech Health plc, a biotherapeutics company, today announces that its Founded Entity, Sonde Health (“Sonde”), a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organization focused on the Indian Pharmaceutical market, to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India. This deal represents Sonde’s first partnership with a

Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organization focused on the Indian Pharmaceutical market, to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India. This deal represents Sonde’s first partnership with a pharmaceutical company. As part of this arrangement, Koye will leverage Sonde’s vocal biomarker

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate was founded in 2019 by a team of neuroscience industry veterans to address the increasingly urgent need for more effective treatments for CNS disorders, and to overcome long-standing challenges in CNS drug development. Since its founding, the company has acquired a robust port

InnoCare Pharma  and Keymed Biosciences  of CM369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by a joint venture between the two companies called Tiannuojiancheng Pharma, has been approved by the China’s National Medical Products Administration (NMPA). CM369 is a potential first-in-class drug co-developed by InnoCare and Keymed as a monotherapy or in combination with other therapies for the treatment of various cancers. CCR8 is a

Hansa Biopharma AB, "Hansa" , a pioneer in enzyme technology for rare immunological conditions, and its partner Medison Pharma, "Medison", a global pharmaceutical company focused on providing access to highly innovative therapies for patients in international markets, today announced that the Polish Ministry of Health has agreed to include Idefirix® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation. This decisio

CSL Vifor and Travere Therapeutics, Inc. today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023. “The acceptance of the EU regu

Astex Pharmaceuticals, Inc. (Astex) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the initial treatment of adults with acute myeloid leukemia (AML) who are not candidates for standard induction chemotherapy. The current standard of care for AML is hospital-administered intravenous (IV) chemotherapy infusions or, for those patients not

Vifor Fresenius Medical Care Renal Pharma today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no.